← Oncology Approval Tracker

FDA DECISION ·

Opdualag

nivolumab and relatlimab-rmbw · Bristol Myers Squibb

FDA approvalNew therapyMelanoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and pediatric patients age 12 or older with melanoma that is unresectable or metastatic.

LAMPGEN ANALYSIS

Why it matters

A fixed-dose combination targets both PD-1 and LAG-3 in advanced melanoma.

What research teams should watch

Review age and weight-specific labeling and align immune toxicity education and follow-up with infusion workflows.

PRIMARY RECORDS

Sources